Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFLECT-3 rosiglitazone XR adjunctive therapy study in APOE ε4-stratified mild to moderate Alzheimer's disease
2006-001402-92Phase 3Completed
- Sponsor
- GSK
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Rosiglitazone XR plus acetylcholinesterase inhibitor with Placebo plus acetylcholinesterase inhibitor (2 arms). Primary endpoints: Cognitive function and Overall clinical response. Started Jul 2006; status: completed.
02
Drugs
rosiglitazone
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-001402-92.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001402-92.